Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients
Crossref DOI link: https://doi.org/10.1007/s00415-016-8177-1
Published Online: 2016-06-03
Published Print: 2016-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Iaffaldano, Pietro
Viterbo, Rosa Gemma
Trojano, Maria
License valid from 2016-06-03